MannKind Corporation
Last updated September 27, 2026
Organization details
- Legal name
- MannKind Corporation
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Danbury
- Headquarters state / province
- Connecticut
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- MNKD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000899460
- EIN
- 13-3607736
Board of directors
-
Anthony C. Hooper · DirectorSince 2023
-
Christine Mundkur · DirectorSince 2023
-
James Samuel Shannon · DirectorSince 2023
-
Jennifer Grancio · DirectorSince 2023
-
Kent Kresa · DirectorSince 2023
-
Michael A. Friedman · DirectorSince 2023
-
Michael Castagna · Director · Chief Executive OfficerSince 2023
-
Ronald J. Consiglio · DirectorSince 2023
-
Sabrina Kay · DirectorSince 2023
-
Steven B. Binder · DirectorSince 2024
Chief executives
Michael Castagna
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of May 20, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
90.4%
-
90.8%
-
91.5%
-
91.8%
-
91.8%
-
92.1%
-
92.1%
-
92.5%
-
92.6%
Board connections
5 of this board's directors also sit on 7 other boards.
- via Anthony C. Hooper
- via Christine Mundkur
- via Sabrina Kay
- via Sabrina Kay
- via Kent Kresa
- via James Samuel Shannon
- via James Samuel Shannon
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $259,000
- 1 purchase by 1 insider
- Sold, last 12 months
- $3,127,268
- 13 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 10, 2026 | Steven B. Binder Director | Open-market sale | −33,558 | $3.81 | $127,856 |
| Aug 7, 2026 | Steven B. Binder Director | Open-market sale | −39,051 | $4.06 | $158,547 |
| Jul 17, 2026 | Steven B. Binder Director | Open-market sale | −52,485 | $4.06 | $213,089 |
| Jul 17, 2026 | Thomson David Officer (EVP Genl Counsel & Secretary) | Open-market sale | −24,109 | $4.05 | $97,641 |
| Jul 15, 2026 | Steven B. Binder Director | Option exercise | +93,790 | — | — |
| Jul 15, 2026 | Michael Castagna Director, Officer (Chief Executive Officer) | Option exercise | +350,260 | — | — |
| Jul 15, 2026 | Thomson David Officer (EVP Genl Counsel & Secretary) | Option exercise | +93,790 | — | — |
| Jul 15, 2026 | Singh Sanjay R Officer (EVP Technical Operations) | Option exercise | +70,550 | — | — |
| Jul 15, 2026 | Tross Stuart A Officer (Chief People & Workpl Officer) | Option exercise | +93,790 | — | — |
| Jul 15, 2026 | Marasco Dominic Officer (Pres, Endocrine Business Unit) | Shares withheld for tax | −3,623 | $4.09 | $14,818 |
| Jul 15, 2026 | Prentiss Christopher B Officer (Chief Financial Officer) | Shares withheld for tax | −11,572 | $4.09 | $47,329 |
| Jul 15, 2026 | Steven B. Binder Director | Shares withheld for tax | −15,688 | $4.09 | $64,164 |
| Jul 15, 2026 | Michael Castagna Director, Officer (Chief Executive Officer) | Shares withheld for tax | −192,819 | $4.09 | $788,630 |
| Jul 15, 2026 | Thomson David Officer (EVP Genl Counsel & Secretary) | Shares withheld for tax | −51,632 | $4.09 | $211,175 |
| Jul 15, 2026 | Singh Sanjay R Officer (EVP Technical Operations) | Shares withheld for tax | −22,047 | $4.09 | $90,172 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.